Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2020 · 10-Q
Revenue$17.64M$17.64M+1,895.9% vs Q1 2019 Net Income-$40.04M-$40.04MN/M vs Q1 2019 EPS Diluted-$1.08-$1.08N/M vs Q1 2019 Operating Income-$37,700,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived-$40,203,000N/M Margins · derivedOperating margin-213.7%+3848.1 pt vs Q1 2019
Net margin-226.9%+3418.8 pt vs Q1 2019
ended Mar 31, 2020 · filed May 7, 2020 · 37 d after period end